Stock Events

Stock Events

Search...

Compass Pathways

$6.63

189

-$0.1-1.49% Friday 20:00

Statistics

Day High

6.78

Day Low

6.35

52W High

12.75

52W Low

5.01

Volume

720,150

Avg. Volume

444,601

Mkt Cap

511.54M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

1AugExpected

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

-0.69

-0.46

-0.23

0

Expected EPS

-0.53

Actual EPS

-0.56

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CMPS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

MindMed develops psychedelic-inspired medicines, directly competing in the psychedelic therapy space with Compass Pathways.

ATAI Life Sciences N.V.

ATAI Life Sciences works on developing psychedelic and non-psychedelic compounds for mental health, a direct competitor in the psychedelic medicine field.

GH Research is focused on developing 5-MeO-DMT therapies for mental health disorders, competing in the same therapeutic area as Compass Pathways.

Cybin Inc. is working on psychedelic drug development for mental health conditions, making it a competitor in the psychedelic-based treatment market.

Revive Therapeutics

Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, making it a competitor in the psychedelic therapy market.

Seelos Therapeutics

Seelos Therapeutics works on developing therapies for central nervous system disorders and other rare diseases, indirectly competing with Compass Pathways in the broader mental health treatment market.

Analyst Ratings

55.25$Average Price Target

The highest estimate is $120.

From 5 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

About

Finance

Financial Conglomerates

Health Technology

Biotechnology

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Show more...

CEO

Employees

186

Country

US

ISIN

US20451W1018

Listings